PDGF inhibits BMP2-induced bone healing

Area of Science:

• Regenerative Medicine
• Skeletal Biology
• Cell Signaling

Background:

• Bone regeneration relies on stem/progenitor cells and signaling pathways.
• Platelet-derived growth factor (PDGF) signaling via PDGF receptor beta (PDGFRβ) is known to inhibit bone morphogenetic protein 2 (BMP2)-induced osteogenesis in vitro.

Purpose of the Study:

• To evaluate the in vivo effects of PDGF and BMP2 on bone healing.
• To determine if inhibiting PDGF signaling improves BMP2-mediated bone regeneration.

Main Methods:

• Utilized in vivo bone healing models.
• Investigated outcomes of PDGF BB and BMP2 treatments.
• Examined targeted deletion of PDGFRβ in alpha-smooth muscle actin (αSMA) osteoprogenitors.

Main Results:

• Targeted deletion of PDGFRβ in osteoprogenitors increased callus bone mass and improved fracture biomechanics.
• BMP2 treatment increased osteoprogenitors, while combined PDGF BB and BMP2 treatment decreased progenitor numbers.
• BMP2 treatment enhanced osteoblast numbers; combined PDGF BB and BMP2 treatment reduced osteoblast numbers.

Conclusions:

• In vivo, PDGF inhibits BMP2-induced osteogenesis.
• Early inhibition of PDGF signaling does not enhance BMP2-induced bone healing.
• PDGF signaling negatively impacts BMP2-driven bone formation and osteoprogenitor availability.